This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Onapristone

Arno Therapeutics, Inc.

Drug Names(s): IVV-1001

Description: Onapristone is an oral, anti-progestin hormone blocker that has been shown to have considerable anti-tumor activity in breast cancer. Arno Therapeutics and Leica Biosystems are co-developing a companion diagnostic (CDx) for onapristone.

Deal Structure: Arno and Invivis
In February 2012, Arno announced that it has signed an exclusive, worldwide licensing agreement with Invivis to develop onapristone for the treatment of breast cancer. Pursuant to the terms of the license agreement, Arno will pay Invivis certain research, clinical and regulatory milestone payments as well as royalties on net sales of licensed products. In addition to the license agreement, Arno will receive certain clinical development support services from Invivis pursuant to a separate agreement.

Arno and Leica
In January 2014, Arno Therapeutics and Leica Biosystems entered into a co-development agreement for the development of a companion diagnostic (CDx) for Arno's lead compound and personalized therapy, onapristone. Under the terms of the co-development agreement, Arno will sponsor and conduct clinical trials for onapristone. Leica will develop and validate the CDx for APR with responsibility for ensuring the investigational CDx kit...See full deal structure in Biomedtracker

Partners: Invivis Pharmaceuticals


Onapristone News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug